NMTR 9 Meters Biopharma Inc.

1.15
-0.04  -3%
Previous Close 1.19
Open 1.19
52 Week Low 0.43
52 Week High 2.26
Market Cap $288,156,012
Shares 250,570,445
Float 187,513,598
Enterprise Value $260,558,224
Volume 2,497,138
Av. Daily Volume 8,987,488
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NM-002
Short bowel syndrome
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Larazotide
Celiac disease
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previously announced underwritten public offering of 34,500,000 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $1.00 per share.

    The net proceeds to the Company from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by 9 Meters, were approximately $31.5 million.

    Citigroup and William Blair & Company, L.L.C. acted as joint book-running managers for the offering. Truist Securities, Inc. also acted as a joint book-running…

    RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previously announced underwritten public offering of 34,500,000 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $1.00 per share.

    The net proceeds to the Company from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by 9 Meters, were approximately $31.5 million.

    Citigroup and William Blair & Company, L.L.C. acted as joint book-running managers for the offering. Truist Securities, Inc. also acted as a joint book-running manager for the offering. BMO Capital Markets served as financial advisor to the Company.

    The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-249268) that was declared effective by the Securities and Exchange Commission (the "SEC") on October 9, 2020. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 800 831 9146, email: , from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing , or from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, or emailing . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About 9 Meters Biopharma

    9 Meters Biopharma, Inc. (the "Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

    Forward-Looking Statements

    This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the Company's expected use of the net proceeds from the offering and its need to raise additional capital even after this offering; (ii) uncertainties associated with the clinical development and regulatory approval of product candidates; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's 2020 merger and its acquisition of Naia Rare Diseases, Inc. in 2020, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Corporate Contact:

    Edward J. Sitar, Chief Financial Officer
    9 Meters Biopharma, Inc.

    Media Contact:

    Amy Jobe, Ph.D.
    LifeSci Communications, LLC

    315-879-8192

    Investor Contact:

    Corey Davis, Ph.D.
    LifeSci Advisors, LLC

    212-915-2577

    SOURCE: 9 Meters Biopharma



    View source version on accesswire.com:
    https://www.accesswire.com/639024/9-Meters-Biopharma-Announces-Closing-of-Offering-of-Common-Stock

    View Full Article Hide Full Article
  2. RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on April 5, 2021, subject to customary closing conditions.

    The gross proceeds to the Company from the public offering, before deducting underwriting discounts and commissions and offering expenses payable…

    RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on April 5, 2021, subject to customary closing conditions.

    The gross proceeds to the Company from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by 9 Meters, are expected to be approximately $30 million.

    Citigroup and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Truist Securities, Inc. is also acting as a joint book-running manager for the offering. BMO Capital Markets is serving as financial advisor to the Company.

    The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-249268) that was declared effective by the Securities and Exchange Commission (the "SEC") on October 9, 2020. A preliminary prospectus supplement related to the offering has been filed with the SEC and a final prospectus supplement with the final terms of the offering will be available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146, email: , from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing , or from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, or emailing . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.

    About 9 Meters Biopharma

    9 Meters Biopharma, Inc. (the "Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

    Forward-Looking Statements

    This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) risks related to the satisfaction of customary closing conditions for the offering, the Company's expected use of the net proceeds from the offering and its need to raise additional capital even after this offering; (ii) uncertainties associated with the clinical development and regulatory approval of product candidates; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's 2020 merger and its acquisition of Naia Rare Diseases, Inc. in 2020, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Corporate contacts

    Edward J. Sitar, Chief Financial Officer
    9 Meters Biopharma, Inc.

    Media contact

    Amy Jobe, Ph.D.
    LifeSci Communications, LLC

    315-879-8192

    Investor contact

    Corey Davis, Ph.D.
    LifeSci Advisors, LLC

    212-915-2577

    SOURCE: 9 Meters Biopharma



    View source version on accesswire.com:
    https://www.accesswire.com/638324/9-Meters-Biopharma-Prices-Public-Offering-of-Common-Stock

    View Full Article Hide Full Article
  3. RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. All of the shares in the proposed offering are to be sold by 9 Meters Biopharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Citigroup and…

    RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. All of the shares in the proposed offering are to be sold by 9 Meters Biopharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Citigroup and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Truist Securities, Inc. is also acting as a joint book-running manager for the offering. BMO Capital Markets is serving as financial advisor to the Company.

    The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-249268) that was declared effective by the Securities and Exchange Commission (the "SEC") on October 9, 2020. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146, email: , from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing , or from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, or emailing . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.

    About 9 Meters Biopharma
    9 Meters Biopharma, Inc. (the "Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

    For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

    Forward-Looking Statements
    This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) risks related to the satisfaction of customary closing conditions for the proposed offering, the Company's expected use of the net proceeds from the proposed offering and its need to raise additional capital even after this proposed offering; (ii) uncertainties associated with the clinical development and regulatory approval of product candidates; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's 2020 merger and its acquisition of Naia Rare Diseases, Inc. in 2020, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Corporate contacts
    Edward J. Sitar, Chief Financial Officer
    9 Meters Biopharma, Inc.

    www.9meters.com

    Media contact
    Amy Jobe, Ph.D.
    LifeSci Communications, LLC

    315-879-8192

    Investor contact
    Corey Davis, Ph.D.
    LifeSci Advisors, LLC

    212-915-2577

    SOURCE: 9 Meters Biopharma



    View source version on accesswire.com:
    https://www.accesswire.com/638273/9-Meters-Biopharma-Announces-Proposed-Public-Offering-of-Common-Stock

    View Full Article Hide Full Article
    • FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure
    • Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS
    • Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life
    • Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment
    • Raised over $58 million from prominent institutional healthcare investors in 2020

    Research & Development Day on Short Bowel Syndrome planned for tomorrow (March 23

    • FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure
    • Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS
    • Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life
    • Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment
    • Raised over $58 million from prominent institutional healthcare investors in 2020

    Research & Development Day on Short Bowel Syndrome planned for tomorrow (March 23rd) at 11:00 AM ET - see https://media.rampard.com/20210323/reg.jsp for registration details

    RALEIGH, NC / ACCESSWIRE / March 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today provided an overview of its recent achievements and 2021 outlook and reported its financial results for the fourth quarter and full year ended December 31, 2020.

    Full Year & Recent Business Highlights

    After a recent productive FDA interaction in Q1 2021, the Company plans to move forward using total stool output (TSO) as the primary efficacy endpoint in an upcoming Phase 2 trial, which we plan to begin in Q2 and report final data in Q4.

    • Multi-center, placebo-controlled, randomized, multiple fixed-dose study in approximately 20 adult SBS patients
    • Primary endpoint: total stool output (TSO) compared to baseline
    • Numerous secondary endpoints including nutritional and fluid status

    Announced positive Phase 1b/2a topline data for NM-002, a proprietary long-acting GLP-1, for short bowel syndrome. In December, the Company reported data that we believe demonstrated the potential to meaningfully improve the quality of life of SBS patients by improving stool output and reducing reliance on parenteral support. The study evaluated the safety and tolerability of three escalating fixed doses of NM-002 (50 mg, 100 mg, 150 mg) in 9 adults with SBS over 56 days.

    • Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume and bowel movement frequency.
    • Additional analyses to be discussed in more detail on the Company's R&D day on March 23rd including parenteral support, pharmacokinetics and quality of life.
    • Twice-monthly fixed-dosing regimen exhibited an excellent safety and tolerability profile.

    Larazotide Phase 3 Update

    • Enrollment continuing in Phase 3 celiac disease clinical trial
    • Given challenges in enrollment related to the COVID-19 pandemic, interim results and topline data readouts are anticipated in 2022.

    Raised more than $58 million in equity financings and warrant exercises in 2020 with an additional $6.7 million in proceeds from warrants exercised in Q1 2021, demonstrating continued support of management from long-term institutional healthcare investors:

    • In May, the Company announced the closing of a $22.5 million private placement led by Orbimed Advisors, LLC.
    • In December, the Company announced a successful stock offering generating net proceeds of approximately $32 million led by Adage Capital Partners GP, LLC.

    John Temperato, President & CEO of 9 Meters Biopharma, commented: "In 2020, we delivered on our plan to establish 9 Meters as a leading innovator in the treatment of rare and unmet gastroenterology disorders. We continue to advance both of our co-lead GI assets and enhance our earlier stage pipeline of GI products. After a successful Phase 1b/2a trial with NM-002 in SBS, we are pleased that after consultation with the FDA we will begin dosing in a Phase 2 trial utilizing total stool output (TSO) as the primary endpoint. We continue patient enrollment in the Phase 3 larazotide program and are looking forward to the interim analysis in and final topline data in 2022."

    Program Updates and Anticipated Milestones for 2021 and 2022

    NM-002 (proprietary long-acting GLP-1 agonist):

    • Initiate Phase 2 study in Q2 2021
    • Anticipated USAN/INN name in Q2 2021
    • Topline Phase 2 results in Q4 2021
    • Initiation of Phase 3 Study in Q4 2021

    Larazotide:

    • Interim analysis for Phase 3 anticipated in 2022
    • Topline readout Phase 3 anticipated in 2022

    NM-003 (proprietary long acting GLP-2 agonist):

    • Received Orphan Drug designation from FDA for prevention of acute graft versus host disease (aGvHD)
    • Progressing into IND-enabling work in 2021

    NM-102 (proprietary tight-junction microbiome modulator):

    • Announced positive preclinical data in a gut microbiome-mediated immune checkpoint inhibitor melanoma model in 2020
    • Progressing into IND-enabling work in 2021

    Full Year Financial Results

    As of December 31, 2020, the Company's cash and cash equivalents totaled approximately $37.9 million, compared to approximately $4.6 million on December 31, 2019. Additionally, $6.7 million in proceeds were received by the Company from warrant exercises in the first quarter of 2021 (through March 19th).

    The Company reported a net loss of approximately $5.0 million, or $0.03 per share, for the fourth quarter of 2020, compared to a net loss of approximately $8.9 million, or $0.25 per share for the fourth quarter of 2019. The Company reported a net loss of approximately $61.5 million, or $0.58 per share, for the year ended December 31, 2020, compared to a net loss of approximately $27.0 million, or $0.81 per share, for the year ended December 31, 2019.

    About 9 Meters Biopharma
    9 Meters Biopharma, Inc. 9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

    For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

    Forward-looking Statements This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Corporate contacts

    Edward J. Sitar, Chief Financial Officer
    9 Meters Biopharma, Inc.

    www.9meters.com

    Media contact

    Veronica Eames
    LifeSci Communications, LLC

    203-942-4626

    Investor contact

    Corey Davis, Ph.D.
    LifeSci Advisors, LLC

    212-915-2577

    SOURCE: 9 Meters Biopharma



    View source version on accesswire.com:
    https://www.accesswire.com/636701/9-Meters-Biopharma-Provides-Business-Update-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2020

    View Full Article Hide Full Article
  4. Tuesday, March 23rd @ 11am Eastern Time

    RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time.

    The webinar will feature presentations by KOLs Carol Rees Parrish, M.S., R.D.N., University of Virginia Health, and 9 Meter's management who will discuss the current development status of NM-002. Additional topics will include the following:

    • Short Bowel Syndrome Overview
    • Clinical Impact of Chronic Diarrhea in SBS
    • Potential Paradigm…

    Tuesday, March 23rd @ 11am Eastern Time

    RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time.

    The webinar will feature presentations by KOLs Carol Rees Parrish, M.S., R.D.N., University of Virginia Health, and 9 Meter's management who will discuss the current development status of NM-002. Additional topics will include the following:

    • Short Bowel Syndrome Overview
    • Clinical Impact of Chronic Diarrhea in SBS
    • Potential Paradigm Shift to treatment with GLP-1
    • Phase 1b/2a Results Recap
    • Clinical & Regulatory Path Forward

    NM-002 is a long-acting injectable GLP-1 receptor agonist that utilizes the proprietary XTEN® technology to extend circulating half-life. This is designed specifically to slow digestive transit time in SBS patients by reducing upper GI motility and improving the chronic diarrhea frequently associated with a shortened intestine. 9 Meters previously announced positive topline Phase 1b/2a data in adult patients suffering from SBS in December and is now moving into subsequent trials to develop the compound for this high unmet need.

    A live Q&A session will follow the formal presentations. To register for the webinar, please click here.

    Carol Rees Parrish, M.S., R.D.N. has 30 years of clinical experience, the past 20 years of which have been spent specializing in nutrition support and GI disorders at the University of Virginia Health, Digestive Health Center of Excellence. Carol founded the Medicine Nutrition Support Service in 1991, began the home nutrition support program at the University of Virginia Health Home Health Company, developed the GI Nutrition Clinic, originated the Celiac Support Group, and is the co-founder of both nutrition support traineeship programs. She has been the nutrition series editor for the popular Practical Gastroenterology Journal's Nutrition Series since 2003.

    Previously, she was a clinical nutritionist at Fairfax Hospital from 1981-1990 and a nutrition counselor at multiple practices from 1984-1990. Ms. Parrish received her Bachelor of Science from the University of California, Davis, and a Master of Science from Rosalind Franklin University of Medicine and Science. She completed her general internship at Milwaukee County Medical Complex.

    In addition to being a member of many professional affiliations, Ms. Parrish has written multiple abstracts, chapters, and publications.

    About 9 Meters Biopharma

    9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

    For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

    Forward-looking Statements

    This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended September 30, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Corporate contact

    Edward J. Sitar
    Chief Financial Officer
    9 Meters Biopharma, Inc.

    www.9meters.com

    Media contact

    Amy Jobe, Ph.D.
    LifeSci Communications, LLC

    315-879-8192

    Investor contact

    Corey Davis, PhD
    LifeSci Advisors, LLC

    212-915-2577

    SOURCE: 9 Meters Biopharma



    View source version on accesswire.com:
    https://www.accesswire.com/635193/9-Meters-Biopharma-Hosting-Key-Opinion-Leader-Webinar-on-Short-Bowel-Syndrome-and-NM-002-Program-Update

    View Full Article Hide Full Article
View All 9 Meters Biopharma Inc. News